Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:18 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2737–2760 of 33,183 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo Clear all

Conditions: Myocardial Infarction
Interventions: Percutaneous Coronary Intervention (PCI), RO4905417, placebo; Procedure · Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 19 Years to 74 Years
Enrollment: 532 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 35
States / cities: Huntsville, Alabama • Tucson, Arizona • Los Angeles, California + 31 more

Conditions: Previously Untreated Stage IV Non-Squamous Non Small Cell Lung Cancer
Interventions: AZD1775, AZD1775 Matching Placebo, pemetrexed, carboplatin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 8
States / cities: Englewood, Colorado • Fort Myers, Florida • Orlando, Florida + 5 more

Conditions: Cystic Fibrosis
Interventions: recombinant human IGF-1, Placebo; Drug
Lead sponsor: Stony Brook University; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Stony Brook, New York

Conditions: Influenza A
Interventions: LD Sing2016 M2SR H3N2 influenza vaccine, MD Sing2016 M2SR H3N2 influenza vaccine, HD Sing2016 M2SR H3N2 influenza vaccine, LD Bris10 M2SR H3N2 influenza vaccine, Placebo; Biological · Other
Lead sponsor: FluGen Inc; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 206 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 4
States / cities: Hollywood, Florida • Lenexa, Kansas • Lexington, Kentucky + 1 more

Conditions: Immune-Mediated Necrotizing Myopathy
Interventions: Gamunex-C, Albumin; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 120 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Muscle Spasticity
Interventions: botulinum toxin Type A, Normal Saline; Biological · Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 468 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 2
States / cities: Downey, California • Daytona Beach, Florida

Conditions: Hemorrhagic Fever With Renal Syndrome
Interventions: HTNV/PUUV DNA vaccine, Placebo, TriGrid Delivery System (TDS); Biological · Device
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 18 Years to 49 Years
Enrollment: 130 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Silver Spring, Maryland

Conditions: Congenital Heart Disease, Cardiopulmonary Bypass
Interventions: Acetaminophen; Other
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 1 Day to 17 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Autoimmune Diseases, Systemic Inflammatory Process, Knee Pain Chronic, Osteoarthritis, Rheumatoid Arthritis
Interventions: Fish Oil, Vitamin D, placebo pill; Drug · Dietary Supplement · Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 50 Years and older
Enrollment: 25,871 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Common Cold, Pharyngitis
Interventions: Acetylsalicylic Acid (Aspirin Complex, BAYE4465) + Pseudoephedrine, Acetylsalicylic Acid (Aspirin, BAYE4465), Pseudoephedrine, Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1,016 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 2
States / cities: New York, New York

Conditions: Depression
Interventions: Keto-like supplement, Placebo; Dietary Supplement
Lead sponsor: Laureate Institute for Brain Research, Inc.; Other
Eligibility: 18 Years to 65 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Tulsa, Oklahoma

Conditions: Type 2 Diabetes Mellitus
Interventions: exenatide, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 21 Years to 75 Years
Enrollment: 182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 40
States / cities: Birmingham, Alabama • La Jolla, California • San Mateo, California + 37 more

Conditions: Amputation, Chronic Pain
Interventions: morphine and mexiletine; Drug
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 18 Years to 85 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2003
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Rheumatoid Arthritis
Interventions: ALX-0061, Placebo, Methotrexate; Biological · Other · Drug
Lead sponsor: Ablynx, a Sanofi company; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 345 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 22
States / cities: Birmingham, Alabama • Hemet, California • La Palma, California + 18 more

Conditions: Type 2 Diabetes Mellitus, Cardiovascular Disease, Hypertension, Inadequate Glycaemic Control
Interventions: Dapagliflozin, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 45 Years and older
Enrollment: 922 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 60
States / cities: Gulf Shores, Alabama • Phoenix, Arizona • Burbank, California + 57 more

Conditions: Myelodysplastic Syndromes
Interventions: Tamibarotene, Placebo, Azacitidine; Drug
Lead sponsor: Syros Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 246 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 22
States / cities: Tucson, Arizona • Los Angeles, California • New Haven, Connecticut + 17 more

Conditions: Colon Cancer
Interventions: Perifosine, Capecitabine, Perifosine Placebo; Drug · Other
Lead sponsor: AEterna Zentaris; Industry
Eligibility: 18 Years and older
Enrollment: 381 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 49
States / cities: Tucson, Arizona • Beverly Hills, California • Deer Park, California + 45 more

Conditions: Hypertension
Interventions: Valsartan 0.25 mg/kg, Valsartan 1.0 mg/kg, Valsartan 4.0 mg/kg; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 6 Months to 5 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: USA, New Jersey

Conditions: Asthma Placebo Effects
Interventions: albuterol, placebo inhaler, placebo acupuncture; Drug · Procedure
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 80 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Cytomegalovirus Infections
Interventions: AVX601, Placebo; Biological
Lead sponsor: AlphaVax, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Healthy
Interventions: Ad26.ZIKV.001 5*10^10 vp, Ad26.ZIKV.001 1*10^11 vp, Placebo; Biological
Lead sponsor: Janssen Vaccines & Prevention B.V.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 2
States / cities: Lenexa, Kansas • Boston, Massachusetts

Conditions: Alcohol Use Disorder, Mild Traumatic Brain Injury
Interventions: Magventure MagProX100 with MagOption stimulator and Magpro Cool Coil B65 A/P; Device
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 22 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Hines, Illinois

Conditions: Type 2 Diabetes
Interventions: Liraglutide; Drug
Lead sponsor: Temple University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2023
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Delirium, Respiratory Depression, Overmedication
Interventions: Verum Acupuncture, Sham Acupuncture; Device
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Portland, Oregon

Search by objective public record fields.

A Study of RO4905417 in Patients With Non ST-Elevation Myocardial Infarction (Non-STEMI) Undergoing Percutaneous Coronary Intervention

Ph II Trial of Carboplatin and Pemetrexed With or Without AZD1775 for Untreated Lung Cancer

IGF-1 Therapy in Patients With Cystic Fibrosis

Safety and Immunogenicity of the Bris10 M2SR and Sing2016 M2SR H3N2 Monovalent Influenza Vaccines

Monotherapy IVIG Gamunex-C for HMG-CoA Reductase Auto-Antibody Positive Necrotizing Myopathy Treatment (The MIGHT Trial)

BOTOX® Treatment in Adult Patients With Post-Stroke Lower Limb Spasticity

Phase 2a Immunogenicity Study of Hantaan/Puumala Virus DNA Vaccine for Prevention of Hemorrhagic Fever

Acetaminophen for Oxidative Stress After Cardiopulmonary Bypass

Vitamin D and Fish Oil for Autoimmune Disease, Inflammation and Knee Pain

Placebo and Active Controlled Study to Assess Efficacy and Tolerability of Aspirin Plus Pseudoephedrine

Evaluation of a Keto-Like Supplement on Brain Responses to Emotional Stimuli in Depression

Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using Thiazolidinediones or Thiazolidinediones and Metformin

Efficacy of Opioids and Mexiletine for the Treatment of Postamputation Pain

A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis

Efficacy and Safety in Patients With Type 2 Diabetes Mellitus, Cardiovascular Disease and Hypertension

Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome

Placebo-Controlled Study of Perifosine + Single Agent Chemotherapy for Metastatic Cancer Patients

Dose Response of Valsartan on Sitting Systolic Blood Pressure in Children 6 Months - 5 Years of Age With High Blood Pressure

Characterization of Placebo Responses in Stable Asthma

A Clinical Trial of an Alphavirus Replicon Vaccine for Cytomegalovirus (CMV)

A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Ad26.ZIKV.001 in Healthy Adult Volunteers

rTMS Target Identification for Functional Disability in AUD+mTBI

Effects of Liraglutide on ER Stress in Obese Patients With Type 2 Diabetes

Acupuncture for Sedation in the Intensive Care Unit (ICU)